MetaCap

Relmada Therapeutics (RLMD) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics is the larger company by market cap ($279.5 million vs $264.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RLMD-58.61%VCRE-42.12%
+6%-28%-62%
Jul 6, 20261 yearNov 20, 2026
RLMD-59.13%VCRE-31.75%
+3%-30%-62%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RLMD versus VCRE key metrics
MetricRLMDVCRE
Share price$2.62$9.41
Market cap$279.54M$264.89M
1-day change-15.76%-5.09%
YTD return-45.76%—
1-year return-38.64%—
5-year return-86.09%—
EPS (TTM)$-0.73$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-57.39M—
52-week high$8.00$17.80
52-week low$2.60$7.88
Distance from 52-week high-67.25%-47.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+310.31%+158.90%
Average volume1.45M23.31K
Shares outstanding106.69M28.16M
Employees1750
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

RLMD vs VCRE FAQ

Which is bigger, Relmada Therapeutics or Vicore Pharma AB?

Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $264.89M for Vicore Pharma AB (VCRE).

Are Relmada Therapeutics and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons